Prescriber Scope of Practice for Weight Loss/GLP-1 in New York

If you’re a psychiatrist or PMHNP watching the GLP-1 boom and wondering whether you can legally prescribe semaglutide, phentermine, or other weight-loss medications via telehealth — you’re not alone. The answer is: yes, but with important caveats that depend on your state, your scope of practice, and whether the medication is a controlled substance.

This isn’t a simple yes-or-no question. Federal DEA rules are in flux, state telehealth laws vary wildly, and psychiatric providers face unique scope-of-practice considerations when treating obesity. Let’s break down exactly what you need to know to prescribe weight-loss medications legally and safely via telemedicine in 2025-2026.

The Federal Picture: DEA Telehealth Extensions Through 2026

Here’s the headline: The DEA and HHS extended COVID-era telehealth flexibilities through December 31, 2026, allowing providers to prescribe controlled substances via telemedicine without a prior in-person exam. This was the fourth extension — explicitly designed to prevent a ‘telehealth cliff’ while permanent regulations are finalized.

What this means for you:

• You can currently prescribe Schedule III-V controlled substances (like phentermine, a common appetite suppressant) via telehealth to new patients nationwide — no in-person visit required at the federal level
• GLP-1 agonists (semaglutide/Wegovy, tirzepatide/Zepbound) are not controlled substances — they can be prescribed via telehealth with zero federal restrictions beyond standard prescribing requirements
• This flexibility ends December 31, 2026 unless new rules supersede it

The catch: States can — and do — impose stricter requirements. Federal permission doesn’t override state medical board rules.

The DEA is working on permanent telemedicine prescribing regulations. Proposed rules would create a ‘Special Registration’ pathway for providers to prescribe Schedule III-V controlled substances via telehealth, and might allow limited Schedule II prescribing for specialists like psychiatrists (think ADHD stimulants). But until those rules are finalized, the current extension governs.

Bottom line for weight loss: Phentermine can be prescribed via telehealth federally (through 2026). GLP-1s have no federal telehealth restrictions at all.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State Telehealth Laws: Where It Gets Complicated

Federal rules set the floor — states set the ceiling. Some states effectively require in-person exams for controlled substances even during the federal waiver period. Others are wide open.

New York: Strictest State for Controlled Substances

New York requires at least one in-person medical evaluation before prescribing any controlled substance to a patient. This is a state Department of Health regulation (10 NYCRR §80.63, updated May 2025).

Limited exceptions:

• A different NY-licensed provider examined the patient in person within the last 12 months and shared records
• You’re covering for a colleague who saw the patient in person
• Emergency situation with an existing patient relationship (5-day supply max)

Practical impact: If you’re a New York psychiatrist wanting to prescribe phentermine (Schedule IV) for weight loss via telehealth, you generally cannot do so to a new patient without seeing them in person first or meeting one of the exceptions.

For non-controlled weight-loss meds: GLP-1s are fair game via telehealth in NY. Standard evaluation required (preferably video), but no in-person mandate.

New York also mandates checking the state Prescription Monitoring Program within 24 hours before prescribing any Schedule II, III, or IV controlled substance — every single prescription.

Florida: Permissive for Telehealth (With Detailed Obesity Rules)

Florida’s telehealth statute (§456.47) actually allows Schedule II prescribing via telehealth for psychiatric treatment — meaning Florida psychiatrists can prescribe Adderall for ADHD remotely. For weight loss, the most common controlled substance (phentermine) is Schedule IV, which Florida’s telehealth law doesn’t restrict.

Florida’s obesity prescribing requirements apply to ALL providers (physicians, supervised NPs, PAs):

1. BMI threshold: Patient must have BMI ≥30, or ≥27 with comorbidities, or body fat >25% (male) / >30% (female)
2. Initial evaluation: History, physical exam (can be telehealth), necessary tests — all documented
3. Written informed consent: Must outline risks of weight-loss medications
4. Quarterly follow-ups: Patient must be re-evaluated at least every 3 months while on anti-obesity meds
5. Consumer Bill of Rights: Must provide Florida’s ‘Weight-Loss Consumer Bill of Rights’ to each patient

PDMP: Florida requires checking the E-FORCSE database before prescribing any controlled substance to patients ≥16 years old.

For psychiatrists: You have full authority to prescribe weight-loss medications, but you must follow these obesity treatment standards just like any physician. Document the BMI, get the consent, schedule the quarterly check-ins.

California: Telehealth-Friendly, CPOM-Strict

California law allows telehealth exams to satisfy the ‘appropriate prior examination’ requirement for prescribing. No state-level in-person mandate for controlled substances if standard of care is met via video.

Key California requirements:

• Telehealth consent: Must obtain and document patient consent for telehealth services (B&P §2290.5)
• CURES PDMP: Must check California’s CURES database before first prescription of any Schedule II-IV drug and at least every 4 months for ongoing therapy
• E-prescribing: All prescriptions must be electronic (implemented 2022)

Corporate Practice of Medicine: California strictly prohibits non-physicians from owning or controlling medical practices. Any weight-loss telehealth service must be physician-owned or use a compliant MSO structure.

NP scope: California NPs operate under Standardized Procedures with physician supervision, unless they qualify for independent practice under AB 890 (phased in through January 2026). A Psychiatric NP treating obesity would typically need physician oversight from someone with appropriate expertise (family medicine, endocrinology).

Insurance note: California’s Medi-Cal will stop covering GLP-1 medications for weight loss in January 2026, classifying them as non-covered. This will likely push more patients to cash-pay telehealth models.

Texas: Standard of Care Rules, Delegation Requirements

Texas has no in-person exam requirement for telehealth prescribing. A valid patient relationship can be established via live video or store-and-forward technology with audio.

Texas requirements:

• Synchronous interaction: Audio-video exam preferred; online questionnaire alone is insufficient
• Follow-up coordination: Must provide follow-up instructions and, with patient consent, send a report to the patient’s PCP within 72 hours
• PDMP: Must check Texas PMP (AWARxE) for controlled substances; while phentermine isn’t on the mandatory-check list by statute, best practice is to check for any controlled drug

NP/PA delegation: Texas NPs and PAs must have a Prescriptive Authority Agreement with a Texas-licensed physician. The agreement must include protocols for weight-loss drugs if they’ll prescribe them. NPs/PAs cannot prescribe Schedule II in Texas except in hospital/hospice settings, but phentermine (Schedule IV) is permitted under proper delegation.

Corporate practice: Texas prohibits corporate practice of medicine. Telehealth services must be physician-owned or use compliant structures.

Pennsylvania & Illinois: Federal-Plus Approaches

Pennsylvania: No comprehensive telehealth statute, but practice is permitted under professional standards. PA defers to federal DEA rules on controlled substance prescribing. Must check PA PDMP before first opioid/benzo prescription and each time thereafter. CRNPs require collaborative agreements; no independent practice yet.

Illinois: Very telehealth-friendly. Explicitly allows relationship establishment via telehealth, permits audio-only in some cases. APRNs can obtain Full Practice Authority after 4,000 hours, allowing independent prescribing including controlled substances. Must check IL PMP for Schedule II narcotics. No special state rules on weight-loss prescribing beyond standard medical practice.

Psychiatrist vs PMHNP: Scope of Practice for Weight Loss

Psychiatrists (MD/DO): Full Authority, Clinical Considerations

As a fully licensed physician, you have broad prescribing authority. You can legally prescribe FDA-approved weight-loss medications or use GLP-1s off-label — even though obesity treatment isn’t your specialty.

The reality:

• Many psychiatrists already address weight management tangentially (patients gaining weight from antipsychotics, binge-eating disorder cases)
• You might prescribe metformin or GLP-1s to mitigate medication-induced weight gain
• This falls within your scope because you hold an unrestricted medical license

But — and this is critical — medical boards will hold you to the same standard of care as any physician treating obesity:

• Document appropriate indications (BMI ≥30 or ≥27 with comorbidities)
• Perform or obtain necessary evaluations (vital signs, relevant labs like thyroid function, lipid panel)
• Provide or coordinate behavioral counseling for diet and exercise
• Schedule appropriate follow-ups (many states like Florida mandate quarterly; best practice is monthly early in treatment)
• Address contraindications and drug interactions (e.g., phentermine’s effects on anxiety, heart rate in psychiatric patients)

Clinical considerations psychiatrists face:

• Phentermine is a stimulant — can worsen anxiety, trigger mania in bipolar patients, cause insomnia
• GLP-1s have GI side effects and affect glucose metabolism — consider interactions with psychiatric meds that affect weight/metabolism
• You’ll need to incorporate nutrition counseling or referrals (some states like New Jersey explicitly require documented diet/exercise counseling alongside prescriptions)

Collaboration is smart: Many psychiatrists prescribe weight-loss medications in consultation with the patient’s PCP or an endocrinologist. This coordination is encouraged by medical boards and reduces your liability for managing conditions outside your daily practice.

PMHNPs: Tread Carefully on Scope

A Psychiatric-Mental Health Nurse Practitioner is educated and certified to treat mental health conditions. Prescribing purely for obesity might be viewed by nursing boards as outside your scope of practice.

State-by-state scope considerations:

Texas & Florida: Scope of practice is tied to what a reasonably prudent practitioner with similar training would do. A Florida PMHNP would likely need:

• A supervising physician’s sign-off to manage a weight-loss program
• That physician should have appropriate expertise (family practice, endocrinology) to satisfy regulatory expectations

California: NPs practice under Standardized Procedures or (as of 2026) can attain independent practice. But independent practice is in your population focus — a psych-certified NP prescribing solely for obesity without dual certification or additional training could face professional risk.

New York: NPs can practice independently after 3,600 hours, but must stay within clinical competence. Treating obesity may require informal collaboration with primary care or additional training/certification.

The safe approach for PMHNPs:

• Obtain additional certification in obesity medicine or weight management
• Work under protocols with a physician experienced in obesity treatment
• Focus on patients where psychiatric and weight management overlap (binge-eating disorder, medication-induced weight gain, depression with metabolic syndrome)
• Document your rationale and competence carefully

Don’t assume your DEA and NP prescribing authority automatically extend to obesity treatment — even if technically ‘legal’ to prescribe the medications, boards expect you to practice within your training.

The Economics: Why Telehealth Platforms Beat DIY Marketing

Let’s talk numbers — because this is where many providers get stuck.

The DIY marketing reality for psychiatric and weight-loss care:

Acquiring a qualified patient through self-directed marketing typically costs $200-500+ per patient when you factor in:

• Agency/consultant fees for SEO and PPC management
• Ad spend testing and optimization ($15-40+ per click for mental health/weight-loss keywords)
• Staff time handling and qualifying leads
• No-show rates from cold leads
• 6-12 months of SEO investment before meaningful patient flow
• Failed campaigns and wasted budget

Google Ads for weight-loss keywords are expensive and most clicks don’t convert. A realistic cost per booked patient through PPC is $200-400+.

Directory listings (Psychology Today, Zocdoc) charge monthly fees AND you compete with hundreds of providers on the same page. Zocdoc charges $35-100+ per booking, but total monthly cost including subscription adds up. You’re still paying whether patients book or not.

SEO takes 6-12 months of consistent investment before generating results. Most solo providers don’t have the expertise or patience for this.

Klarity Health’s model removes this entire risk:

Instead of spending $3,000-5,000/month on marketing with uncertain results, you pay a standard listing fee only when a pre-qualified patient books with you. That’s guaranteed ROI versus gambling on marketing channels.

Key advantages:

• No upfront marketing spend or monthly subscription fees
• Pre-qualified patients already matched to your specialty and availability
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule — only pay when you see patients

For providers starting out or scaling an existing practice, a platform that handles patient acquisition removes the financial risk entirely. You can focus on clinical care while the platform delivers patients who are already interested in your services.

Staying Compliant: Practical Checklist

Regardless of your state or provider type:

✅ Verify patient location at each visit — ensure you’re licensed in that state

✅ Obtain telehealth consent if required (California, Illinois, and others mandate documented consent)

✅ Conduct and document a thorough evaluation:

• Relevant history (prior weight loss attempts, medical conditions, medications)
• Mental status exam for psychiatry
• Documented weight, BMI, vital signs where obtainable
• Justification for treatment (why weight loss is indicated)

✅ Follow state-specific prescribing protocols:

• Florida: BMI documentation, informed consent, quarterly follow-ups
• New York: In-person exam for controlled substances or meet exceptions
• All states: PDMP checks where required

✅ Use PDMP and e-prescribing systems:

• Check your state’s prescription monitoring database before controlled substance prescriptions
• Use certified e-prescribing systems (required in most states now)

✅ Coordinate care:

• Inform (with patient consent) the patient’s PCP
• Consider referrals for nutrition counseling, cardiology, endocrinology as appropriate
• Document all coordination efforts

✅ Avoid false advertising:

• Don’t guarantee specific weight loss amounts
• Don’t claim ‘FDA approved’ for compounded medications
• Be transparent about costs, program duration, risks

FAQ

Q: Can I prescribe semaglutide (Wegovy, Ozempic) for weight loss via telehealth as a psychiatrist?

Yes. GLP-1 agonists are not controlled substances, so they have no federal telehealth restrictions. You must meet your state’s standard of care for prescribing (appropriate evaluation, documentation of indication, patient consent where required). Since you’re a physician, you have full authority — just ensure you’re following obesity treatment protocols (documenting BMI ≥30 or ≥27 with comorbidities, scheduling follow-ups, monitoring for side effects).

Q: What about phentermine? It’s a controlled substance.

Federally, you can prescribe phentermine via telehealth through December 31, 2026 under the DEA extension. But state rules vary:

• New York: Generally requires in-person exam for controlled substances
• Florida, Texas, California: Permit telehealth prescribing of Schedule IV substances like phentermine if standard of care is met
• All states: Must check PDMP, use e-prescribing, document appropriately

Q: As a PMHNP, can I offer weight-loss treatment?

Technically you can prescribe the medications if you have prescriptive authority, but treating obesity may be outside your usual scope as a psychiatric provider. Best approach:

• Work under physician supervision/collaboration with someone experienced in weight management
• Consider additional certification in obesity medicine
• Focus on overlapping cases (psychiatric patients with weight issues)
• Document your competence and rationale thoroughly

Some states’ nursing boards may scrutinize PMHNPs treating purely medical conditions like obesity without appropriate oversight or training.

Q: Do I need to see weight-loss patients in person at all?

Depends on state and medication:

• For non-controlled GLP-1s: Most states allow pure telehealth if you meet standard of care (video exam preferred)
• For controlled substances (phentermine): New York requires in-person; most other states currently allow telehealth under federal waiver
• Best practice: Even if not required, consider hybrid models — at least one in-person visit for complex cases or to build patient relationship, then telehealth follow-ups

Q: What follow-up schedule do I need?

• Florida: Quarterly (every 3 months minimum) for patients on anti-obesity meds
• Virginia: Within 30 days of starting therapy
• Best practice/national guidelines: Monthly follow-ups early in treatment to monitor response, side effects, and adjust dosing; can extend to quarterly once stable

Q: What if my state doesn’t have specific obesity prescribing rules?

Follow the standard of care — which generally means:

• Document BMI/indication
• Rule out contraindications (cardiovascular disease for phentermine, history of pancreatitis for GLP-1s)
• Provide or refer for nutrition/exercise counseling
• Regular monitoring of weight, vital signs, relevant labs
• Informed consent discussion

Look to resources like the American Board of Obesity Medicine or Obesity Medicine Association guidelines.

Q: Can I prescribe to patients in other states via telehealth?

Only if you’re licensed in those states. No federal telehealth license exists (outside federal systems). You must obtain licensure in each state where your patients are located. Interstate Medical Licensure Compact can streamline this process if your state participates.

Ready to Start Seeing Weight Loss Patients?

If you’re a psychiatrist or PMHNP looking to expand into weight management — or you’re already treating psychiatric patients who need weight-loss medications — the regulatory landscape is navigable with the right approach.

The core requirements:

• License in the patient’s state
• Appropriate evaluation via telehealth (video preferred)
• Follow state-specific protocols for obesity treatment
• PDMP checks and e-prescribing for controlled substances
• Documentation matching standard of care
• Coordination with primary care when appropriate

Klarity Health handles the patient acquisition piece, delivering pre-qualified patients interested in weight management or psychiatric care to your virtual practice. No upfront marketing spend. No subscription fees. Just pay when patients book.

Join Klarity’s Provider Network to start seeing telehealth patients in your licensed states — whether you’re focused on psychiatric care, weight management, or the intersection of both.

Sources and References

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated